Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

PREDICT-IV · Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics

FP7Status: CLOSED1 May 200831 October 2013EU funding €11,330,906

The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early development will be delivered. Margins-of-safety will be deduced and the data generated by the proposed approach may also identify early biomarkers of human toxicity for pharmaceuticals. The results obtained in Predict-IV will enable pharmaceutical companies to create a tailored testing strategy for early drug safety. The project will integrate new developments to improve and optimize cell culture models for toxicity testing and to characterize the dynamics and kinetics of cellular responses to toxic effects in vitro. The target organs most frequently affected by drug toxicity will be taken into account, namely liver and kidney. Moreover, predictive models for neurotoxicty are scarce and will be developed. For each target organ the most appropriate cell model will be used. The approach will be evaluated using a panel of drugs with well described toxicities and kinetics in animals and partly also in humans. This approach will be highly advantageous as it will allow a direct comparison between the in vivo to the in vitro data. A parallel analysis of several dynamic and kinetic models with a broad spectrum of endpoints should allow for the identification of several relevant biomarkers of toxicity. Inter-individual susceptibilities will be taken into account by integrating the polymorphisms of the major drug metabolizing enzymes and correlating the observed effects in the human cell models with their genotype. Environmental influences on cellular toxicity to these compounds will also be evaluated using hypoxic stress as a relevant test model.

Consortium · 20 organisations

coordinator

JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG

DE · €1,638,469

participant

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

IE · €482,652

participant

NEUROPROOF GMBH

DE · €311,173

participant

UNIVERSITE DE LAUSANNE

CH · €471,862

participant

CERTARA UK LIMITED

UK · €245,199

participant

INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES - INERIS

FR · €446,167

participant

NOVARTIS PHARMA AG

CH · €800,496

participant

ISTITUTO SUPERIORE DI SANITA

IT · €436,152

participant

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

DE · €346,784

participant

PARIS-LODRON-UNIVERSITAT SALZBURG

AT · €850,096

participant

MEDIZINISCHE UNIVERSITAT INNSBRUCK

AT · €918,216

participant

UNIVERSITAET ROSTOCK

DE · €551,202

participant

UNIVERSITEIT UTRECHT

NL · €369,347

participant

UNIVERSITE D'ARTOIS

FR · €395,811

participant

FREIE UNIVERSITAET BERLIN

DE · €268,928

participant

UNIVERSITE DE RENNES I

FR · €352,512

participant

KaLy-Cell

FR · €548,380

participant

EMERGENTEC BIODEVELOPMENT GMBH

AT · €875,160

participant

Merck KGaA

DE · €873,974

participant

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

BE · €148,326

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.